Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical
Amatha Sreedevi1, S Smitha Prabhu2, Virendra S Ligade1
1Department of Pharmaceutical Regulatory Affairs and Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka State, India.
Abstract:
Topical dosage forms are widely used to treat various skin disorders, but increase healthcare costs because of the limited number of generic competitors. The development of a generic version of complex topical products is facing several scientific and regulatory challenges related to demonstrating bioequivalence, advanced physicochemical characterization, and the requirement of clinical endpoint equivalence. This narrative review explores the contemporary scientific and regulatory approaches used for BE assessment of topical generics, with a greater focus on in vitro alternatives and Q3 microstructural characterization. The integration of quality by design principles can support the development of robust Q3-based BE strategies. Key in vitro tools such as IVRT, IVPT, and dermal PBPK modeling are emerging approaches for identifying scientific parameters for regulatory acceptability and overcoming these methodological challenges. Case studies involving bifonazole, acyclovir, clotrimazole, and innovative vehicles such as Recura illustrate the practical challenges of existing regulatory frameworks and the increasing use of in vitro and Q3-based approaches. This review highlights the critical gaps in harmonizing global regulatory requirements and underscores the need to foster early regulatory engagement and standardize methodological protocols. Together, these initiatives pave the way for a more predictable, scientifically sound, and cost-effective regulatory environment. This transformation is essential for improving access, reducing development timelines, and advancing the future of topical generic medicines.
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Oral Drug Delivery Systems: Introduction
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Ophthalmic Drug Delivery Systems

